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Abstract
Background: Anti-cyclic citrullinated peptide (CCP) anti-
body is emerging as an important diagnostic marker for rheu-
matoid arthritis (RA). We evaluated the analytical and
diagnostic performance of the ARCHITECT anti-CCP
(Abbott Diagnostics), a new fully automated chemilumines-
cent microparticle immunoassay.
Methods: Serum samples from 69 patients with RA and 86
non-RA patients were used to evaluate the performance of
the ARCHITECT anti-CCP assay, and the results were com-
pared with those of EliA CCP (Phadia). The optimal cut-off
value was calculated using receiver operating characteristic
(ROC) curve analysis.
Results: Within-run and total imprecision (%CV) of the
ARCHITECT anti-CCP were -6% and good linearity was
observed over the claimed range. The areas under the ROC
curves for the ARCHITECT anti-CCP and EliA CCP were
0.90 and 0.89, respectively. The sensitivity and specificity
were 76.8% and 95.3% for the ARCHITECT anti-CCP and
78.3% and 95.3% for EliA CCP using the manufacturer’s
cut-off thresholds. Both assays showed sensitivity of 84.1%
and specificity of 94.2% using the optimal cut-off values.
Conclusions: The analytical performance of the ARCHI-
TECT anti-CCP was satisfactory and diagnostic performance
was comparable to that of EliA CCP. The use of optimal cut-
off thresholds can yield higher sensitivity with minimal loss
of specificity.
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Introduction
Rheumatoid arthritis (RA) is one of the most common sys-
temic autoimmune diseases, affecting about 1% of the pop-
ulation. It is characterized by chronic inflammation of the
synovium, which often leads to progressive joint destruction
and disability (1). The presence of rheumatoid factor (RF) is
one of the criteria used by the American College of Rheu-
matology (ACR) for the classification of RA (2). Although
the RF test has good sensitivity for RA, it lacks specificity
as it can be detected in other rheumatic or inflammatory
disease, and even in healthy individuals, particularly the
elderly (3).
Recently, anti-cyclic citrullinated peptide (CCP) antibodies
have emerged as a useful marker to predict erosive arthritis
and early RA due to their high specificity (4–6). A number
of tests using different cyclic citrullinated antigens have been
developed with varying degrees of analytical and diagnostic
performance (7–12).
In the clinical laboratory, in addition to clinically con-
firmed diagnostic performance, application in a fully auto-
mated format, enabling for rapid testing with minimal user
associated errors and good analytical performance, is impor-
tant. Recently, the ARCHITECT anti-CCP assay (Abbott
Laboratories, Abbott Park, IL, USA), a newly developed ful-
ly automated chemiluminescent microparticle immunoassay
was introduced. The goal of this study was to evaluate the
analytical (imprecision, linearity) and diagnostic (sensitivity
and specificity) performance of the ARCHITECT anti-CCP
assay and to compare the results of the ARCHITECT anti-




A total of 155 serum samples were collected from April 2009 to
September 2009 at Seoul National University Hospital. Sixty-nine
serum samples were obtained from the rheumatology clinic out-
patients who were diagnosed with RA based on the ACR criteria
(2) (10 males and 59 females, median 59 years, age range
25–77 years). Eighty-six patients without RA, consisting of 34
patients with connective tissue diseases w17 systemic lupus erythe-
matosus (SLE), 9 Sjögren’s syndrome, 5 Behcet’s disease, 3 der-¸
matomyositisx, 15 with other rheumatic disease (5 ankylosing
spondylitis, 3 Takayasu’s arteritis, 3 osteoarthritis, 2 polymyalgia
rheumatica, 2 palindromic rheumatism); 31 patients with various
viral infections (11 hepatitis B virus, 10 hepatitis C virus, 8 Epstein-
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Table 1 Imprecision of the ARCHITECT anti-CCP assay.
Mean, U/mL Within-run Between-day Total
CV, % CV, % CV, %
Pool 1 (low) 3.4 5.5 2.4 5.9
Positive control (medium) 24.5 1.7 3.2 3.8
Pool 2 (high) 118.2 3.0 3.4 4.9
CV, coefficient of variation.
Barr virus, and 2 cytomegalovirus), and six patients with other dis-
ease (2 gout, 1 relapsing polychondritis, 1 Raynaud’s disease, 1
scleroderma, 1 psoriasis) (33 males and 53 females, median
50 years, age range 17–84 years) were also collected. All serum
samples were stored at –208C until analysis. This study was
approved by the Institutional Review Board of Seoul National Uni-
versity Hospital.
Methods
Imprecision Within-run, between-day, and total coefficient of
variation (%CV) for the ARCHITECT anti-CCP was assessed in
accordance with the Clinical and Laboratory Standards Institute
(CLSI) document EP15-A2 (13). Imprecision was evaluated using
two serum samples (low and high antibody concentration) and one
positive control material (medium antibody concentration).
Linearity The linearity evaluation was performed according to
CLSI document EP6-A (14). Briefly, patient samples with low and
high antibody concentrations were selected and mixed in 4:0, 3:1,
2:2, 1:3, 0:4 ratios to produce five concentrations that were related
in linear fashion and measured in duplicate.
Anti-CCP antibody assays
All serum samples were tested with the EliA CCP assay (Phadia
AB, Uppsala, Sweden) using the ImmunoCAP 100 instrument and
with the ARCHITECT anti-CCP assay (Abbott Laboratories, Abbott
Park, IL, USA) using the ARCHITECT i2000. The characteristics
of both assays are as follows: the EliA CCP is a fluoroenzyme
immunoassay with polystyrene wells coated with original second
generation synthetic CCP. The conjugate used is b-galactosidase-
mouse monoclonal anti-human IgG and the substrate is 4-methyl-
umbelliferyl-b-D-galactoside. All the procedures are automated
with a serum dilution of 1:100 and total incubation time of 97 min
(30, 28, and 39 min for serum, conjugate, and substrate incubations,
respectively). Six calibrators with range of 0.4–340.0 EliA U/mL
are used; the ARCHITECT anti-CCP assay is a chemiluminescent
immunoassay that uses microparticles coated with the same second
generation synthetic CCP used by the EliA CCP. The conjugate used
is sulfopropyl acridinium amide-labeled polyclonal mouse anti-
human IgG. Pretrigger (containing 1.32% hydrogen peroxide) and
trigger (containing 0.35N sodium hydroxide) solutions are added to
detach the side groups of the sulfopropyl acridinium amide and
make the acridinium luminescent. All procedures are automated
with total incubation time of 29 min (7, 18, and 4 min for predi-
lution, serum incubation, and conjugate incubation, respectively).
Six calibrators with range of 0.0–200.0 U/mL are used. All meas-
urements were performed according to the manufacturer’s recom-
mendations and performed by experienced operators who were
blinded to the results of the other tests.
Statistical analysis
The sensitivity and specificity of each method was calculated using
both the cut-off value recommended by the manufacturer (G5
U/mL for ARCHITECT anti-CCP and )10 EliA U/mL for the EliA
CCP) and the optimal cut-off value that showed the highest sum of
sensitivity and specificity determined by receiver operating char-
acteristic (ROC) curve analysis. The areas under the ROC curve
(AUC) and 95% CI were compared using the Mann-Whitney rank
sum test. Correlation of the ARCHITECT anti-CCP and EliA CCP
results were evaluated using Spearman’s test and Bland-Altman
analysis (15), after excluding results that exceeded the measurable
range. Statistical analysis was performed using SPSS for Windows
(version 12.0; SPSS Inc, Chicago, IL, USA). In preparing this
report, the STARD guidelines (16) were taken into consideration
when possible.
Results
Analytical performance of ARCHITECT anti-CCP assay
Within-run, between-day, and total CV (%) were 1.7%–
5.5%, 2.4%–3.4%, and 3.8%–5.9%, respectively (Table 1).
The highest imprecision was found at low antibody concen-
trations. Linearity was confirmed over the range of
0.95–194.6 U/mL for the ARCHITECT anti-CCP assay
(ys1.004x–3.083, rs0.999, p-0.0001) (Figure 1).
Diagnostic performance of ARCHITECT anti-CCP
and EliA CCP assay
The diagnostic performance for differentiating patients with
RA from those without RA was evaluated using ROC curve
analysis. The AUCs were 0.90 (95% CI, 0.85–0.96) for the
ARCHITECT anti-CCP and 0.89 (95% CI, 0.82–0.95) for
the EliA CCP, with no statistically significant difference
between them (Figure 2).
The sensitivities, specificities, positive and negative pre-
dictive values determined using the manufacturer’s and opti-
mal cut-off values, defined as that with the highest sum of
sensitivity and specificity, are shown in Table 2. Using the
manufacturer’s cut-off values, the sensitivity and specificity
was 76.8% and 95.3%, respectively, for the ARCHITECT
anti-CCP and 78.3% and 95.3%, respectively, for the EliA
CCP. Both assays showed better diagnostic performance
(sensitivity of 84.1% and specificity of 94.2% for both
assays) using the optimal cut-off values (G2.6 U/mL for
ARCHITECT anti-CCP and G4.8 EliA U/mL for EliA
CCP).
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Figure 1 Linearity of the ARCHITECT anti-CCP assay.
The linearity was confirmed over the range of 0.95–194.6 U/mL
for the ARCHITECT anti-CCP assay (ys1.004x–3.083, rs0.999,
p-0.0001).
Figure 2 Receiver-operating characteristic (ROC) curves for the
ARCHITECT anti-CCP and EliA CCP assay based on 69 patients
with RA and 86 non-RA patients.
The area under the ROC curve (AUC) was 0.90 (95% CI,
0.85–0.96) for the ARCHITECT anti-CCP assay and 0.89 (95% CI,
0.82–0.95) for the EliA CCP method. With optimal cut-off values
(highest sum of sensitivity and specificity, G2.6 U/mL for ARCHI-
TECT anti-CCP and G4.8 EliA U/mL for EliA CCP), the sensitivity
and specificity were 84.1% and 94.2%, respectively, for both assays.
Despite the high specificity of the anti-CCP assays, false
positive results were observed in four patients (3 SLE and 1
palindromic rheumatism) with both assays. The distribution
of anti-CCP antibody concentrations using a log scale in
patients with and without RA is shown in Figure 3. The
antibody concentrations for false positive results were high,
17.4–57.8 U/mL for the ARCHITECT anti-CCP assay and
37–148 EliA U/mL for the EliA CCP method.
Comparison of ARCHITECT anti-CCP and EliA CCP
assay
Quantitative results from the ARCHITECT anti-CCP
(IU/mL) and EliA CCP (EliA U/mL) assays correlated sig-
nificantly, with a Spearman’s correlation coefficient (rs) of
0.860 (p-0.0001). Linear regression analysis showed a
slope of 1.988 and an intercept of –0.010 (Figure 4A). A
Bland-Altman bias plot showed an average difference of
–26.6 (95% CI, –131.4–78.2) between data pairs from these
two assays, with the difference increasing as anti-CCP anti-
body concentrations increased (Figure 4B).
Comparing the qualitative results of the two assays with
the manufacturer’s cut-off values showed three discordant
results for the RA group only. Two were negative with the
ARCHITECT anti-CCP assay (2.6 and 4.4 U/mL) but posi-
tive with the EliA CCP (10.9 and 24.2 EliA U/mL). One
sample was positive with the ARCHITECT anti-CCP method
(7.4 U/mL) but negative with the EliA CCP (4.8 EliA
U/mL). Using the optimal cut-off values (G2.6 U/mL for
the ARCHITECT anti-CCP and G4.8 EliA U/mL for the
EliA CCP), all results showed concordance.
Discussion
Due to the higher sensitivity and specificity compared to
previous serologic markers, anti-CCP antibodies have
become increasingly important for the diagnosis of RA.
Since the production of the first generation anti-CCP assay
in the early 2000s (7), second generation assays, using a
mixture of synthetic CCPs were introduced with a significant
increase in analytical sensitivity while maintaining very high
specificity (96%) (8). A number of second and third gener-
ation assays are now on the market.
A few comparative studies performed with these assays
(9–12) reported better diagnostic performance for the second
assays that used the original synthetic peptides, irrespective
of their methodological variations, such as conjugate used
and type of substrate. These findings suggest that the anti-
genic source is the most important variable in determining
diagnostic performance. However, the analytical perform-
ance of these second generation anti-CCP assays were still
variable, and sometimes unsatisfactory (9–11).
The ARCHITECT anti-CCP is a newly developed fully
automated chemiluminescent microparticle immunoassay
using the same synthetic peptides used in the original second
generation anti-CCP assay. In this study, the ARCHITECT
anti-CCP test showed good precision and linearity over the
claimed range. Recent studies have reported that high anti-
CCP antibody concentrations at diagnosis can predict a more
severe course of disease (17), and patients with high anti-
CCP concentrations do not respond to treatment with tumor
necrosis factor-a inhibitors (18). These findings indicate that
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Table 2 Comparison of diagnostic performance of the ARCHITECT anti-CCP and EliA CCP assays using the manufacturer’s and optimal
cut-off values.
ARCHITECT anti-CCP EliA CCP
Area under ROC curve (95% CI) 0.90 (0.85–0.96) 0.89 (0.82–0.95)
Manufacturers’ cut-off G5 U/mL )10 EliA U/mL
Sensitivity, % (95% CI) 76.8 (65.1–86.1) 78.3 (66.7–87.3)
Specificity, % (95% CI) 95.3 (88.5–98.7) 95.3 (88.5–98.7)
PPV, % 93.0 93.1
NPV, % 83.7 84.5
Optimal cut-offa G2.6 U/mL G4.8 EliA U/mL
Sensitivity, % (95% CI) 84.1 (73.3–91.8) 84.1 (73.3–91.8)
Specificity, % (95% CI) 94.2 (87.0–98.1) 94.2 (87.0–98.1)
PPV, % 92.1 92.1
NPV, % 88.0 88.0
aBased on the highest sum of sensitivity and specificity. CCP, cyclic citrullinated peptide; PPV, positive predictive value; NPV, negative
predictive value.
Figure 3 Distribution of anti-CCP antibody concentrations on a log scale in patients with and without RA.
The manufacturers’ cut-off values (5 U/mL for ARCHITECT anti-CCP and 10 EliA U/mL for EliA CCP) are shown in dashed lines; RA,
rheumatoid arthritis.
the analytical performance of anti-CCP as a quantitative test
can be important for prognostic and therapeutic reasons.
The diagnostic performances of the ARCHITECT anti-
CCP and EliA CCP assays used in our study were similar to
previous reports on second generation anti-CCP assays using
ELISA (9–11). The EliA CCP has been reported to be a
reliable second generation anti-CCP assay with good diag-
nostic performance (9–11). In our study, the sensitivity and
specificity of the ARCHITECT anti-CCP assay was com-
parable to that of the EliA CCP method when using the
manufacturer’s cut-off thresholds, and exactly the same with
the EliA CCP using optimal cut-off values. The AUC was
even slightly higher with the ARCHITECT anti-CCP (0.90)
compared with the EliA CCP (0.89), although not statisti-
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Figure 4 Correlation between the ARCHITECT anti-CCP and EliA CCP results.
(A) Scatter plot of ARCHITECT anti-CCP and EliA CCP; (B) Bland-Altman plot of ARCHITECT anti-CCP and EliA CCP.
cally significant. Adapting optimal cut-off values can be
useful for the ARCHITECT anti-CCP, considering that it
increases the sensitivity with only a minimal decrease in
specificity. One additional false positive result with the opti-
mal cut-off value was obtained from a SLE patient with
arthralgia.
In our study, four patients in the non-RA group (3 SLE
and 1 palindromic rheumatism) showed false positive results,
with high anti-CCP concentrations measured using both anti-
CCP assays. Among them, two of three SLE patients and
one patient with palindromic rheumatism had polyarthralgia,
including one with radiographic changes. Recent studies
have reported that the positive anti-CCP antibody results may
not be false positives, but rather an important marker in dis-
eases or symptoms related to RA. A study of 266 SLE
patients showed higher anti-CCP positivity in those with
arthritis compared to those without arthritis (42.1% vs. 5.6%)
(19). In another study, among the patients who progressed
from palindromic rheumatism to RA, 83% had anti-CCP
antibody at the time of diagnosis (20). There were no false
positive results in patients with viral infections in our study.
This is in accordance with a previous report which showed
that second generation assays that used the original synthetic
peptides showed higher specificity in patients with viral
infections, compared with other second or third generation
assays that used different citrullinated antigens (11).
The correlation between the ARCHITECT anti-CCP and
EliA CCP was good (rs 0.860) which was similar with pre-
vious reports showing good correlation between different
second generation anti-CCP assays (9, 10). At present, the
quantitative results of anti-CCP assays are not standardized,
and anti-CCP concentrations obtained using different anti-
230 Hwang et al.: Performance of ARCHITECT anti-CCP
Article in press - uncorrected proof
CCP assays cannot be used interchangeably. Preparation of
an international reference may allow for better comparability
between different anti-CCP assays, and better use of results
for diagnostic and prognostic purposes and monitoring of
treatment.
For the first time to our knowledge, we evaluated the ana-
lytical and diagnostic performance of a new fully automated
chemiluminescent microparticle immunoassay, the ARCHI-
TECT anti-CCP assay. It showed good analytical perform-
ance (low imprecision and good linearity) and comparable
diagnostic performance with the EliA CCP assay. The use of
optimal cut-off value may yield higher sensitivity with min-
imal loss of specificity.
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